6-K: Colletion of Recent Announcements
6-K: Colletion of Recent Announcements
6-K: Tolebrutinib Meets Primary Endpoint in HERCULES Phase 3 Study, The First and Only to Show Reduction in Disability Accumulation in Non-relapsing Secondary Progressive Multiple Sclerosis
6-K: Sarclisa Induction Treatment Demonstrated Significantly Improved Progression-Free Survival in Patients with Newly Diagnosed Multiple Myeloma Eligible for Transplant
6-K: Dupixent Approved in the EU as the First-Ever Targeted Therapy for Patients with COPD and NEJM Publishes ALTUVIIIO XTEND-Kids Phase 3 Data Supporting Its Potential to Transform the Treatment Landscape for Children with Severe Hemophilia A
6-K: Colletion of Recent Announcements
6-K: Colletion of Recent Announcements
6-K: Sanofi Completes Acquisition of Inhibrx, Inc
6-K: Colletion of Recent Announcements
Sanofi | S-8: Initial registration statement for securities to be offered to employees pursuant to employee benefit plans
Sanofi | 6-K: New Phase 2b Results for Amlitelimab Support Potential for Best-in-Class Maintenance of Response in Atopic Dermatitis
Sanofi | S-8 POS: S-8 POS
Sanofi | 6-K: Colletion of Recent Announcements
Sanofi | 6-K: Peer Support, Flexible Work Arrangements, Salary for a Year: Sanofi Launches Global Program for Employees Affected by Cancer and Critical Illnesses
Sanofi | 6-K: Dupixent® FDA Approved as First and Only Treatment Indicated for Children Aged 1 Year and Older with Eosinophilic Esophagitis (EoE) and François-Xavier Roger Appointed Chief Financial Officer, Member of Sanofi Executive Committee
Sanofi | 6-K: Sanofi to Acquire Inhibrx, Inc., Adding Potential Best-in-Class Rare Disease Asset for Alpha-1 Antitrypsin Deficiency to Pipeline
Sanofi | 6-K: Brian Foard Appointed Head of Specialty Care Global Business Unit, Member of Sanofi Executive Committee
Sanofi | 6-K: Sanofi Announces End of Program Evaluating Tusamitamab Ravtansine After a 2L NSCLC Phase 3 Trial Did Not Meet a Primary Endpoint
Sanofi | 6-K: Colletion of Recent Announcements
Sanofi | 6-K: Dupixent® Significantly Reduced COPD Exacerbations in Second Positive Phase 3 Trial, Accelerating FDA Submission and Confirming Potential to Become First Approved Biologic for This Serious Disease
No Data
No Data